SR-31742A
SR-31742A, or SR-31742, is a sigma receptor modulator which was under development for the treatment of schizophrenia and manic episodes but was never marketed.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
SR-31742A, or SR-31742, is a sigma receptor modulator which was under development for the treatment of schizophrenia and manic episodes but was never marketed. Its route of administration is unknown. The drug is selective for the sigma receptors and shows high affinity for 3-PPP-labeled sigma receptors (K i = 5.3 nM).
Its selectivity for the sigma σ 1 versus σ 2 receptor is unknown, though it is known to have high affinity for the sigma σ 1 receptor specifically. Whether SR-31742A is an agonist or antagonist of the sigma σ 1 receptor is said to be unknown, though it has been described as an antagonist in some publications.
The drug reduces the hyperlocomotion induced by dextroamphetamine and various other drugs without affecting spontaneous locomotor activity in rodents. SR-31742A was under development by Sanofi-Synthelabo. It reached phase 2 clinical trials for both schizophrenia and manic episodes prior to the discontinuation of its development in 2001.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1367555956 under CC BY-SA 4.0; modifications have been made.